BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia
September 03, 2020 21:42 ET | BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
Metaclipse Therapeutics Awarded Funding from NIAID for COVID-19 Vaccine Development
July 20, 2020 09:00 ET | Metaclipse Therapeutics
ATLANTA, July 20, 2020 (GLOBE NEWSWIRE) -- Metaclipse, a late-stage biotechnology company developing next-generation vaccines with a particular focus on treatments for the elderly, has been awarded...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Receives Approval to Proceed with Phase 2 Trial of its Gelsolin COVID-19 Treatment
July 15, 2020 13:34 ET | BioAegis Therapeutics
MORRISTOWN, N.J., July 15, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., announces that it received regulatory clearance from The Spanish Agency for Medicines and Health Products (AEMPS) for...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Completes Over-Subscribed Financing for COVID-19 Trial
June 23, 2020 17:21 ET | BioAegis Therapeutics
MORRISTOWN, N.J., June 23, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical-stage private company focused on developing therapies for infectious, inflammatory and degenerative...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
Study of BioAegis’ Lead Product, Gelsolin, is Key Component of NIAID Strategic Plan for COVID-19 Research
May 21, 2020 13:58 ET | BioAegis Therapeutics
MORRISTOWN, N.J., May 21, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announces that the National Institute of Health (NIH) Clinical Center is measuring patient gelsolin levels as part of...
red.jpg
RedHill Biopharma Announces Agreement with NIAID to Evaluate RHB-107 Against COVID-19
April 20, 2020 09:00 ET | RedHill Biopharma Ltd.
TEL-AVIV, Israel and RALEIGH, N.C., April 20, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that...
SABIN VACCINE INSTITUTE STRENGTHENS EBOLA SUDAN AND MARBURG VACCINES PROGRAM WITH ADDITIONAL NIAID PARTNERSHIP
March 05, 2020 10:00 ET | The Sabin Vaccine Institute
Washington, DC, March 05, 2020 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute (Sabin) today announced that it has partnered with the Vaccine Research Center (VRC), National Institute of Allergy and...
Navigen logo_LinkedIn_News-01.png
Navigen Announces FDA Clearance of its IND Application to Initiate First-in-Human Studies for CPT31, a Novel, D-peptide HIV Entry Inhibitor
December 10, 2019 08:00 ET | Navigen, Inc.
SALT LAKE CITY, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Navigen, Inc. announced today that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug application ("IND") for...
The Best Thanksgiving
November 26, 2019 17:59 ET | The Children's Inn at NIH
Bethesda, Maryland, Nov. 26, 2019 (GLOBE NEWSWIRE) -- One Texas family has lots to be thankful for this Thanksgiving. Their daughter, now 13, is doing well after undergoing a bone marrow...
AIMLogo.jpg
Hemispherx Biopharma Expands Research on Potential Ebola Treatments to Five Independent Experts/Institutional Collaborators
September 29, 2014 08:30 ET | AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 29, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a widened set of research collaborations designed to develop...